Alogabat (, ; developmental code names RG-7816 and RO7017773) is an ñ<sub>5</sub> subunit-containing GABA<sub>A</sub> receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome. It is taken by mouth.
As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome. It is under development by Roche.